A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Cancer
Interventions
DRUG

Docetaxel

"Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."

DRUG

Capecitabine

"Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."

Trial Locations (1)

15232

University of Pittsburgh Medical Center, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Aventis Pharmaceuticals

INDUSTRY

collaborator

Roche Pharma AG

INDUSTRY

lead

University of Pittsburgh

OTHER